Coherus_Logo_RGB_150.png
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:51 ET | Coherus BioSciences, Inc.
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T...
Coherus_Logo_RGB_150.png
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
May 23, 2024 09:00 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual...
Coherus_Logo_RGB_150.png
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:01 ET | Coherus BioSciences, Inc.
 – Net revenue of $77.1 million in Q1 2024 –  – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million...
Coherus_Logo_RGB_150.png
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 09, 2024 07:30 ET | Coherus BioSciences, Inc.
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® –  REDWOOD CITY, Calif., May 09, 2024 (GLOBE...
Coherus_Logo_RGB_150.png
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 08, 2024 09:00 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study...
Coherus_Logo_RGB_150.png
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024 16:30 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market...
Coherus_Logo_RGB_150.png
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:02 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
Coherus_Logo_RGB_150.png
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
April 08, 2024 08:30 ET | Coherus BioSciences, Inc.
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion ––...
Coherus_Logo_RGB_150.png
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024 16:01 ET | Coherus BioSciences, Inc.
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 –  – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 –  – CIMERLI® net...
Coherus_Logo_RGB_150.png
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024 16:01 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be...